Vitamin D levels differ by cancer diagnosis and decline over time in survivors of childhood cancer

Pediatric Blood and Cancer

Volumn 60, Issue 6, 2013, Pages 949-952

  Rosen, Galit P ^a,b   Beebe, Kristen L ^a,c   Shaibi, Gabriel Q ^a,d  

^a PHOENIX CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Late effects of cancer treatment; Long term survival; Pediatric cancer survivor; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D;

ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; FEMALE; HEPATOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; OSTEOSARCOMA; PRIORITY JOURNAL; RETINOBLASTOMA; SCHOOL CHILD; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

CHILD; FEMALE; HUMANS; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVORS; TIME FACTORS; VITAMIN D;

EID: 84876428011     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24349     Document Type: Article

References (21)

1. Bilariki K, Anagnostou E, Masse V, et al. Low bone mineral density and high incidences of fractures and vitamin D deficiency in 52 pediatric cancer survivors. Horm Res Paediatr 2010; 74: 319-327.
2. Arikoski P, Komulainen J, Riikonen P, et al. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: A 1-year prospective study. J Clin Endocrinol Metab 1999; 84: 3174-3181.
3. Alikasifoglu A, Yetgin S, Cetin M, et al. Bone mineral density and serum bone turnover markers in survivors of childhood acute lymphoblastic leukemia: Comparison of megadose methylprednisolone and conventional-dose prednisolone treatments. Am J Hematol 2005; 80: 113-118.
4. van der Sluis IM, van den Heuvel-Eibrink MM, Hahlen K, et al. Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. J Pediatr 2002; 141: 204-210.
5. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: The childhood cancer survivor study. J Clin Oncol 2001; 19: 3163-3172.
6. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: Retrospective analysis of the childhood cancer survivor study cohort. BMJ 2009; 339: b4606.
7. Ross AC, Taylor CL, Yaktine AL, et al., editors. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academies Press; 2011. 1132 p.
8. Vacek JL, Vanga SR, Good M, et al. Vitamin D deficiency and supplementation and relation to cardiovascular health. Am J Cardiol 2012; 109: 359-363.
9. Simmons JH, Chow EJ, Koehler E, et al. Significant 25-hydroxyvitamin D deficiency in child and adolescent survivors of acute lymphoblastic leukemia: Treatment with chemotherapy compared with allogeneic stem cell transplant. Pediatr Blood Cancer 2011; 56: 1114-1119.
10. Sinha A, Avery P, Turner S, et al. Vitamin D status in paediatric patients with cancer. Pediatr Blood Cancer 2011; 57: 594-598.
11. Othman F, Guo CY, Webber C, et al. Osteopenia in survivors of Wilms tumor. Int J Oncol 2002; 20: 827-833.
12. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-1930.
13. Vieth R. Why the minimum desirable serum 25-hydroxyvitamin D level should be 75nmol/l (30ng/ml). Best Pract Res Clin Endocrinol Metab 2011; 25: 681-691.
14. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006; 81: 353-373.
15. Akeno N, Matsunuma A, Maeda T, et al. Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxylase expression by dexamethasone in mouse kidney. J Endocrinol 2000; 164: 339-348.
16. Dhawan P, Christakos S. Novel regulation of 25-hydroxyvitamin D3 24-hydroxylase (24(OH)ase) transcription by glucocorticoids: Cooperative effects of the glucocorticoid receptor, C/EBP beta, and the vitamin D receptor in 24(OH)ase transcription. J Cell Biochem 2010; 110: 1314-1323.
17. Kurahashi I, Matsunuma A, Kawane T, et al. Dexamethasone enhances vitamin d-24-hydroxylase expression in osteoblastic (UMR-106) and renal (LLC-PK1) cells treated with 1alpha, 25-dihydroxyvitamin D3. Endocrine 2002; 17: 109-118.
18. Kumar J, Muntner P, Kaskel FJ, et al. Prevalence and associations of 25-hydroxyvitamin D deficiency in US children: Nhanes 2001-2004. Pediatrics 2009; 124: e362-e370.
19. Mansbach JM, Ginde AA, Camargo CA, Jr. Serum 25-hydroxyvitamin D levels among US children aged 1 to 11 years: Do children need more vitamin D? Pediatrics 2009; 124: 1404-1410.
20. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the third national health and nutrition examination survey. Am J Hypertens 2007; 20: 713-719.
21. Winzenberg T, Powell S, Shaw KA, et al. Effects of vitamin D supplementation on bone density in healthy children: Systematic review and meta-analysis. BMJ 2011; 342: c7254.